Our data support the clinical testing of targeting DLK1 with an ADC in ACC and other neuroendocrine neoplasms and identify DLK1 as an important cell surface target for future immunotherapeutic approaches. This evidence concerns the gene DLK1 and neuroendocrine neoplasm.